Rallybio Corp (RLYB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $88.03M
Last updated: Nov 17, 2026 at 11:04 AM ET
Rallybio Corp (RLYB) Competitors
The companies most similar to Rallybio are Zura Bio Limited Class A Ordinary Shares (ZURA), TuHURA Biosciences (HURA) and Rani Therapeutics Holdings (RANI). By market cap, Rallybio ranks 7th of the 13 companies on this page; Upstream Bio (UPB) is the largest at $152.38M.
Peer Comparison
RLYB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Rallybio (RLYB) | $88.03M | N/A | 203.1x | 6177.0% | N/A | 0.0% | 0.00% |
| Zura Bio Limited Class A Ordinary Shares (ZURA) | $119.44M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| TuHURA Biosciences Inc (HURA) | $88.58M | N/A | N/A | 0.0% | -81.8% | 0.0% | 0.00% |
| Rani Therapeutics Holdings Inc (RANI) | $60.78M | N/A | 16.3x | 0.0% | N/A | 893.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Tiziana Life Sciences Ltd (TLSA) | $72.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NRX Pharmaceuticals Inc (NRXP) | $95.58M | N/A | 23.8x | 0.0% | N/A | 0.0% | 0.00% |
| Corbus Pharmaceuticals Holding (CRBP) | $69.86M | N/A | 13.9x | 0.0% | -106.7% | -100.0% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Mereo BioPharma Group PLC ADR (MREO) | $49.11M | N/A | 61.3x | 0.0% | -116.6% | 0.0% | 0.00% |
| RenovoRx Inc (RNXT) | $50.18M | N/A | 16.6x | 0.0% | N/A | 300.8% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Peer median | $84.89M | N/A | 16.6x | 0.0% | -116.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Rallybio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Zura Bio Limited Class A Ordinary Shares (ZURA) | Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. | ZURA competitors |
| TuHURA Biosciences Inc (HURA) | TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases. | HURA competitors |
| Rani Therapeutics Holdings Inc (RANI) | Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology... | RANI competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Tiziana Life Sciences Ltd (TLSA) | Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat... | |
| NRX Pharmaceuticals Inc (NRXP) | NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company... | NRXP competitors |
| Corbus Pharmaceuticals Holding (CRBP) | Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target... | CRBP competitors |
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Mereo BioPharma Group PLC ADR (MREO) | Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases... | MREO competitors |
| RenovoRx Inc (RNXT) | RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. | RNXT competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
Frequently Asked Questions About RLYB
Who are Rallybio's main competitors?
The companies most similar to Rallybio include Zura Bio Limited Class A Ordinary Shares (ZURA), TuHURA Biosciences (HURA), Rani Therapeutics Holdings (RANI), Coherus BioSciences (CHRS) and Tiziana Life Sciences (TLSA), listed from the closest match.
Who is Rallybio's biggest competitor?
Upstream Bio (UPB) is the largest of the similar companies at $152.38M; Zura Bio Limited Class A Ordinary Shares (ZURA) is the closest match by business profile, size, sector and industry.
How does RLYB stock compare with its competitors?
RLYB's P/S is 203.1x against a peer median of 16.6x; its net margin is 6177.0% against a peer median of 0.0%.
Which of Rallybio's competitors pays a higher dividend?
Rallybio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Rallybio bigger than its competitors?
No. Rallybio is 7th by market cap among the 13 companies on this page; the largest is Upstream Bio (UPB) at $152.38M.
RLYB pages: Overview, Earnings, Forecast, Financials, Competitors